The FDA announced today that it approved Samsung Bioepis’ Byooviz injection, making it the first approved biosimilar to Lucentis for treating eye diseases. Byooviz (ranibizumab-nuna), the first biosimilar to Lucentis (ranibizumab injection), treats several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (nAMD). The treatment is administered by intravitreal injection (delivered into the […]
Samsung Bioepis Co Ltd
Samsung Biologics IPO could reach $2B, company value above $8B
Biotech drug contract manufacturer Samsung BioLogics could pull in as much as $2 billion through an initial public offering, according to regulatory filings posted this week. The figures would position it as South Korea’s 3rd-largest IPO. BioLogics, which is 47.8% owned by Samsung Electronics (LON:BC94), this week gave new information on the planned offering, which would value the […]
Samsung’s Bioepis considers Nasdaq IPO, seeks funding
(Reuters) – South Korean Samsung‘s (LON:BC94) Bioepis Co Ltd, a developer of generic versions of biotech drugs, said it was considering a Nasdaq IPO – a move that comes as it seeks about $1.3 billion for product development and as the Samsung Group makes a bigger push into biopharmaceuticals. Highlighting growth opportunities for its biopharmaceuticals business may […]
